Published Paper Details:

Nitrosamine impurities have emerged as a major concern in the pharmaceutical industry due to their genotoxic and carcinogenic properties and their potential impact on patient safety. Several incidents involving nitrosamine contamination in marketed medicinal products have prompted regulatory agencies worldwide to establish stringent guidelines for their assessment and control. This study aims to evaluate regulatory management strategies for nitrosamine risk assessment during post-approval changes in pharmaceutical products. The work reviews international regulatory frameworks established by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and International Council for Harmonisation (ICH), with emphasis on risk-based approaches, lifecycle management, and quality risk management principles. The nitrosamine risk assessment process, including risk identification, evaluation, confirmatory analytical testing, risk control, and continuous monitoring, is discussed in detail. Advanced analytical techniques such as LC-MS/MS and GC-MS are highlighted for their role in detecting nitrosamines at trace levels and ensuring compliance with acceptable intake limits. The study further examines the influence of post-approval changes, including modifications in manufacturing processes, raw materials, solvents, packaging systems, and manufacturing sites, on nitrosamine formation. Findings indicate that effective management of nitrosamine risks requires proactive risk assessment, validated analytical methods, robust change control systems, and adherence to evolving regulatory requirements. A multidisciplinary and lifecycle-oriented approach is essential for maintaining pharmaceutical product quality, ensuring regulatory compliance, and protecting public health.